Autologous Dendritic Cell Preparations is under clinical development by Froceth and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Autologous Dendritic Cell Preparations’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Autologous Dendritic Cell Preparations overview
Cell therapy is under development for the treatment of stage III ovarian cancer. The therapeutic candidate comprises autologous dendritic cells. It is administered through subcutaneous route.
For a complete picture of Autologous Dendritic Cell Preparations’s drug-specific PTSR and LoA scores, buy the report here.